RICKY MARC SCHNEIDER, M.D., F.A.C.C., F.A.C.P.

12901 Cariboo Ridge Road, Boynton Beach, FL 33473
Email: rmschneid@ymail.com | Cell phone: 954-464-7414

CURRICULUM VITAE

PROFESSION:

Cardiologist, Medical School Instructor, Expert Witness, Medical Case Reviewer

PLACES OF EMPLOYMENT:

12/20/24 – present	Ricky M. Schneider, M.D. 12901 Cariboo Ridge Road Boynton Beach, FL 33473
12/13/20 – 12/19/24	R. M. Schneider, M.D., P.A. 12901 Cariboo Ridge Road Boynton Beach, FL 33473
4/1/20 - 12/12/20	R. M. Schneider, M.D., P.A. Member of South Florida Surgical Specialists, LLC 7421 N. University Drive, Suite 101 Tamarac, FL 33321
3/6/18 - 3/31/20	R. M. Schneider, M.D., P.A. 7710 NW 71st Court, Suite 303 Tamarac, FL 33321
8/1/11 - 3/5/18	Holy Cross Medical Group 2901 Coral Hills Drive, Suite 240 Coral Springs, FL 33065
8/08 - 8/11	R. M. Schneider, M.D., P.A. Member of Integrated Care, LLC d/b/a Cardiovascular Consultants of South Florida 7421 N. University Drive, Suite 101 Tamarac, FL 33321
9/87 - 7/08	The Broward Heart Group, P.A./University Cardiology Consultants, P.A 7421 N. University Drive, Suite 101 Tamarac, FL 33321

EDUCATION:

John F. Kennedy High School, Plainview, LI, NY; Salutatorian, 6/69

Yale College, New Haven, CT; B.S., Combined Sciences, *Cum Laude*, 6/73

Yale University School of Medicine, New Haven, CT; M.D., 5/77

POST-GRADUATE TRAINING:

Internship and Residency in Internal Medicine
Mount Sinai Medical Center, New York, NY, 7/77 - 6/80

Fellowship in Cardiology
Duke University Medical Center, Durham, NC, 7/80 - 6/83

CERTIFICATION:

Diplomate, Internal Medicine, American Board of Internal Medicine, 9/80

Diplomate, Cardiovascular Disease, American Board of Internal Medicine, 11/83

Diplomate, Certification Board of Nuclear Cardiology, 12/08 - 12/18

Certified for independent licensure to perform Nuclear Cardiology diagnostic procedures, U.S. Nuclear Regulatory Commission, 5/83

Basic Life Support Recertification, 9/19

Advanced Cardiac Life Support Recertification, 9/19

SEAK Certificate of Completion, "How to Excel at Your Expert Witness Deposition," 14 AMA credit hours, 11/19

LICENSURE:

Florida # ME 47659 Expiration Date: January 31, 2025 (inactive PA, NC, NY)

HONORS:

Student Editor, ***Yale Journal of Biology and Medicine***, 7/74 - 6/77

Associate Member, ***Sigma Xi***, Yale University, 1974

Excellence of Research Award, Honorable Mention, National Student Research Forum, University of Texas Medical Branch, Galveston, TE, 5/77

Fellow, American College of Cardiology, 6/85

Fellow, American College of Physicians, 12/90

The Best Doctors in South Florida, ***Miami Metro Magazine***, 10/98

Top Doctors, ***South Florida Consumers' Checkbook Magazine***, 2002, initially

Regional Castle Connolly Top Doctor, Castle Connolly Medical LTD., 2009, 2012

Top Cardiologist, Top Doctors Magazine, 2021, 2022

ACADEMIC AND ADMINISTRATIVE APPOINTMENTS:

Assistant Professor of Clinical Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, 7/83 - 3/86

Assistant, Department of Internal Medicine (Cardiology), Presbyterian-University of Pennsylvania Medical Center, Philadelphia, PA, 7/83 - 1/86

Director of Nuclear Cardiology, Mid-Atlantic Heart and Vascular Institute (now Philadelphia Heart Institute), Philadelphia, PA, 7/83 – 1/86

Instructor, Florida College of Physician Assistants, Coral Springs, FL, 1994 - 1995

Courtesy Clinical Assistant Professor, Department of Medicine, University of Florida College of Medicine, Gainesville, FL, 1995 - 2006

Preceptor, Senior Medical Student Externships in Cardiology, North Broward Hospital District (Coral Springs Medical Center) and University of Florida College of Medicine, 1995 – 2000

Teaching Service Physician, Family Practice Residency Program, University of Florida at North Broward Hospital District (Coral Springs Medical Center), 1995 - 2001

Preceptor, Graduate Nursing Program, School of Nursing, Florida International University, North Miami, FL, 1996 - 1997

Assistant Consulting Professor of Medicine, Duke University Medical Center, Durham, NC, 1997 - present

Preceptor, Pre-baccalaureate Programs, Florida Atlantic University Charles E. Schmidt College of Biomedical Science, Boca Raton, Florida, 2008 – 2011

Clinical Assistant Professor, Department of Internal Medicine, Division of Cardiology, Nova Southeastern University, College of Osteopathic Medicine, Fort Lauderdale, FL, 2009 – 2019

Preceptor, Junior Medical Student Clinical Rotations in Internal Medicine, Nova Southeastern University, College of Osteopathic Medicine, Fort Lauderdale, FL, 2009 - 2017

Preceptor, Junior Medical Student Clinical Rotations in Internal Medicine, Ross University School of Medicine, Commonwealth of Dominica, West Indies, 2012 - 2014

Teaching Faculty, Internal Medicine Residents, University of Miami at Holy Cross Hospital, Fort Lauderdale, FL, 2015 - 2017

Affiliate Faculty of Medicine at Holy Cross Hospital, University of Miami, Miller School of Medicine, Miami, FL, 2016 – 2018

Affiliate Assistant Professor of Clinical Biomedical Science, Florida Atlantic University Charles E. Schmidt College of Medicine, Boca Raton, Florida, 2014 – 2018, 2019 – 2022.

Clinical Affiliate Assistant Professor of Cardiology in the Department of Medicine, Florida Atlantic University Charles E. Schmidt College of Medicine, Boca Raton, Florida, July 1, 2022 – present.

Volunteer Health Care Provider Program (VHCPP) Florida Department of Health, Caridad Center, Boynton Beach, FL, December 22, 2022 - present

PROFESSIONAL ORGANIZATIONS:

American Medical Association

American College of Cardiology

American Heart Association

American Society of Nuclear Cardiology

MEDICAL STAFF COMMITTEES:

Radiation Safety Committee, Presbyterian - University of Pennsylvania Medical Center, Philadelphia, PA, 7/83 - 1/86

House Staff Evaluation Committee, Presbyterian - University of Pennsylvania Medical Center, Philadelphia, PA, 7/83 - 1/86

Pharmacy and Therapeutics Committee, Coral Springs Medical Center, Coral Springs, FL, 1987 - 89

Cardiac Catheterization Committee, Plantation General Hospital, Plantation, FL, 1987 - 88

Cardiac Catheterization Committee, Florida Medical Center, Lauderdale Lakes, FL, 1988 - 95

Special Care Committee, University Hospital and Medical Center, Tamarac, FL, 1988 - 98; Chairman, 1991 – 98

Critical Care Committee, Florida Medical Center, Lauderdale Lakes, FL, 1989 - 96

Critical Care Committee, Northwest Medical Center, Margate, FL, 1989 - 93

Medical Records Committee, Northwest Medical Center, Margate, FL, 1993 - 96

Quality Management Council, University Hospital and Medical Center, Tamarac, FL, 1/94 - 12/97

Medical Executive Committee, University Hospital and Medical Center, Tamarac, FL, 1/98 – 12/11

Vice-Chairman, Department of Medicine, University Hospital and Medical Center, Tamarac, FL, 1/98 - 12/01

Chairman, Department of Medicine, University Hospital and Medical Center, Tamarac, FL, 1/02 - 12/05

Bylaws Committee, University Hospital and Medical Center, Tamarac, FL, 1/05 - 1/07

Bylaws Committee, Coral Springs Medical Center, Coral Springs, FL, 3/09 - 6/09

Secretary/Treasurer, Medical Staff, University Hospital and Medical Center, Tamarac, FL 1/06 - 12/09

Vice-Chief of the Medical Staff, University Hospital and Medical Center, Tamarac, FL, 1/10 - 12/11

Chairman, Credentials and Qualifications Committee, University Hospital and Medical Center, Tamarac, FL, 1/10 - 12/11

Critical Care Committee, Broward Health Coral Springs, Coral Springs, FL, 9/15 - 12/16

OTHER APPOINTMENTS:

Editorial Board, ***The Record***, Official Publication of the Broward County Medical Association, Fort Lauderdale, FL, 1992 - 1995

Vice-President, University Cardiology Consultants, P.A., 1991 - 2000

Board of Directors, Duke University Cooperative Cardiovascular Studies, Durham, NC, 1996 - present (Treasurer, 1999-2005; Vice-President, 2008 - present)

President, South Florida Cardiology Independent Physicians' Association, L.C., 1999 - 2000

Treasurer, The Broward Heart Group, P.A., 2001 – 2008

Participant, National Ambulatory Medical Care Survey, National Center for Health Statistics, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, 2009

Manuscript Reviewer, Consultant to the Editorial Board, CARDIOLOGY, S. Karger AG, Publisher, Basel, Switzerland, 2014 - 2018

SCIENTIFIC PUBLICATIONS:

1. Schneider RM, Hayslett JP, Downing SE, Berger HJ, Donabedian RK, Zaret BL: Effect of methylprednisolone upon technetium-99m pyrophosphate assessment of myocardial necrosis in the canine countershock model. ***Circulation*** 56: 1029-1034, 1977

2. Schneider RM, Worsley A, Lichtman S, Meyer RJ: Sarcoidosis with immune hemolytic anemia and thrombocytopenia: Humoral aberrations responding to steroids or splenectomy. ***Mt. Sinai J Med*** 49:1 15-120, 1982

3. Schneider RM, Seaworth JF, Dohrmann ML, Lester RM, Phillips HR, Bashore TM, Baker JT: Anatomic and prognostic implications of an early positive treadmill exercise test. ***Am J Cardiol*** 50:682-688, 1982

4. Schneider RM, Fornes RE, Stuckey WL, Gilbert RD, Peter RH: Fracture of a polyurethane cardiac catheter in the aortic arch: A complication related to catheter aging. ***Cath and Cardiovasc Diag*** 9: 197-207, 1983

5. Schneider RM, Seaworth JF, Baker JT: Early positive exercise test: Implications for prognosis. ***Primary Cardiol*** 9:49-55, 1983

6. Schneider RM, Roberts KB, Morris KG, Stanfeld JA, Cobb FR: Relation between radionuclide angiographic regional ejection fraction and left ventricular regional ischemia in awake dogs. ***Am J Cardiol*** 53:294-301, 1984

7. Schneider RM, Jaszczak RJ, Coleman RE, Cobb FR: Disproportionate effects of regional hypokinesis on radionuclide ejection fraction: Compensation using attenuation-corrected ventricular volumes. ***J Nucl Med*** 25: 747-754, 1984

8. Schneider RM, Chu A, Akaishi M. Weintraub WS, Morris KG, Cobb FR: Left ventricular ejection fraction after acute coronary occlusion in conscious dogs: Relation to the extent and site of myocardial infarction. ***Circulation*** 72:632-638, 1985

9. Akaishi M. Schneider RM, Mercier RJ, Naccarella FF, Agarwal JB, Helfant RH, Weintraub WS: Relationship between left ventricular global and regional function and extent of myocardial

ischemia in the canine heart. ***J Am Coll Cardiol*** 6: 104-112, 1985

10. Schneider RM, Helfant RH: Tirning of surgery in chronic mitral and aortic regurgitation. (Book Chapter) In: "Valvular Heart Disease," Albert Brest, ed. ***Cardiovascular Clinics*** 361-374, 1985

11. Weintraub WS, Schneider RM, Seelaus PA, Agarwal JB, Helfant RH: Prospective evaluation of the severity of coronary artery disease with exercise radionuclide angiography and electrocardiography. ***Am Heart J*** 111:537-542, 1986

12. Schneider RM, Weintraub WS, Klein LW, Seelaus PA, Katz RI, Agarwal JB, Helfant RH: Multistage analysis of exercise ejection fraction in coronary artery disease. ***Am J Cardiol*** 58:3641, 1986

13. Schneider RM, Weintraub WS, Klein LW, Agarwal JB, Helfant RH: Rate of left ventricular functional recovery by radionuclide angiography after exercise in coronary artery disease**.** ***Am J Cardiol*** 57:927-932, 1986

14. Klein LW, Agarwal JB, Schneider RM, Hermann G. Weintraub WS, Helfant RH: Effects of previous myocardial infarction on measurements of reactive hyperemia and the coronary vascular reserve**.** ***J Am Coll Cardiol*** 8:357-363, 1986

15. Akaishi M. Weintraub WS, Schneider RM, Klein LW, Agarwal JB, Helfant RH: Analysis of systolic bulging: Mechanical characteristics of acutely ischemic myocardium in the conscious dog. ***Circ Res*** 58:209-217, 1986

16. Klein LW, Weintraub WS, Agarwal JB, Schnneider RM, Seelaus P. Katz RI, Helfant RH: Prognostic significance of severe narrowing of the proximal segment of the left anterior descending coronary artery. ***Am J Cardiol*** 58:42-46, 1986

17. Akaishi M. Schneider RM, Mercier RJ, Agarwal JB, Helfant RH, Weintraub WS: Analysis of phases of contraction during graded acute myocardial ischemia. ***Am J Physiol*** 250:H778-785, 1986

18. Akaishi M. Weintraub WS, Mercier RJ, Agarwal JB, Schneider RM, Helfant RH: The significance of underlying coronary stenosis for recovery of myocardial function after transient ischemia in the dog. ***Am Heart J*** 112:1226-1231, 1986

19. Wynant GE, Schneider RM, Akaishi M. Rubenstein RI, Askenase AD, Seelaus PA, Klein LW, Agarwal JB, Weintraub WS, Helfant RH: Experimental and clinical validation of a radionuclide angiographic method for assessing myocardial dyskinesis**.** ***J Nucl Med Technol***, September 1986

20. Klein LW, Agarwal JB, Rosenberg MC, Stets G. Weintraub WS, Schneider RM, Hermann G. Helfant RH: Assessment of coronary artery stenosis by digital subtraction angiography: A pathoanatomic validation. ***Am Heart J*** 113:1011-1017, 1987

21. Schneider RM, Morris KG, Chu A, Roberts KB, Coleman RE, Cobb FR: Relation between

myocardial perfusion and left ventricular function following acute coronary occlusion: Disproportionate effects of anterior vs. inferior ischemia. ***Circ Res*** 60:60-71, 1987

22. Vigilante GJ, Weintraub WS, Klein LW, Schneider RM, Seelaus PA, Parr GVS, Lemole G. Agarwal JB, Helfant RH: Improved survival with coronary bypass surgery in patients with three vessel coronary disease and abnormal left ventricular function: Matched case-control study in patients with potentially operable disease. ***Am J Med*** 82:697-702, 1987

23. Klein LW, Askenase AD, Weintraub WS, Akaishi M. Mercier RJ, Schneider RM, Agarwal J. Helfant RH: Absence of coronary vascular reserve in myocardium distal to a fixed coronary stenosis. ***Cardiovasc Res*** 21:99-106, 1987

24. Akaishi M, Schneider RM, Seelaus PA, Klein LW, Agarwal JB, Helfant RH, Weintraub WS: A non-linear elastic model of contraction of ischemic segments. ***Cardiovasc Res*** 22:889-899, 1988

25. Davidson RM, McNeer JF, Logan L, Higginbotham MB, Anderson J, Blackshear J, Chu A, Hettleman B, McGrew F, Meese R, O'Connor C, Schneider RM, Wagner GS, EXERDUCCS Investigators: A cooperative network of trained sites for the conduct of a complex clinical trial: a new concept in multicenter clinical research. ***Am Heart J*** 151:451-456, 2006

26. Hennekens CH, Schneider WR, Schneider RM. Fish Oils and Stroke. (Book Chapter) In: ***Fatty Acids in Health Promotion and Disease Causation***. Watson RR, ed. *AOCS Press*, Urbana, IL, 2008

27. Hennekens CH, Hetzel S, Pfeffer M, Schneider R, Borzac S, Schneider W, Serebruany, DeMets D: Low-dose enteric coated aspirin does not inhibit thromboxane B2 and prostaglandin E2: data-derived hypothesis formulation. ***Clin Invest*** 2 (7): 747-752, 2012

28. Hetzel S, DeMets D, Schneider RM, Borzak S, Schneider WR, Serebruany V, Schroder H, Hennekens CH: Aspirin increases nitric oxide formation in chronic stable coronary disease. ***J Cardiovasc Pharmacol Ther*** 18 (3): 217-221, 2013

CLINICAL INVESTIGATIONS:

Investigator, *Extended Clinical Evaluation of Lovastatin (EXCEL) Study*. Merck Sharp and Dohme Research Laboratories; Duke University Cooperative Cardiovascular Studies (DUCCS) Consortium, 1988 - 1989 (17 patients enrolled)

Investigator, *The Safety and Efficacy of Cardizem SR in Patients with Mild to Moderate Hypertension*. Marion Laboratories, Inc., 1988 - 1989 (6 patients enrolled)

Investigator, *A Randomized Trial of Intravenous Heparin in Conjunction with Anistreplase (APSAC) in Acute Myocardial Infarction: DUCCS I Study.* Upjohn/SmithKline Beecham Pharmaceuticals, University Hospital, Tamarac, FL, 8/1990 - 7/1991 (6 patients enrolled)

Investigator, *Global Utilization of Streptokinase or rt-PA for Occluded Coronary Arteries (GUSTO Study)*. Genentec Laboratories, University Hospital, Tamarac, FL and Northwest Medical Center, Margate, FL, 1992 - 1993 (respectively, 14 patients and 41 patients enrolled)

Investigator, *Prospective Randomized Amlodipine Survival Evaluation (PRAISE Study), A Randomized, Double-blind, Dose-Titration, Parallel Group, Placebo-Controlled Study to Evaluate the Effect of Amlodipine on Mortality and Morbidity in Patients With Severe Heart Failure, including Extension Phase*. DUCCS consortium, Pfizer Inc., 5/1992 - 12/1994 (11 patients enrolled)

Investigator, *Losartan Exercise Study - US (LEXUS Study), A Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Investigate the Effects of Losartan on the Exercise Capacity and Clinical Status of Patients with Symptomatic Heart Failure - US, Gas Exchange Substudy, including Extension Phase*. DUCCS consortium and Merck & Co., Inc., 5/1994 - 10/1995 (6 patients enrolled)

Investigator, *Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIa and IIb Study)*. Ciba-Geigy Corp., Northwest Medical Center, Margate FL, 2/1994 - 9/1995 (10 patients and 17 patients enrolled in parts IIa and IIb, respectively)

Investigator, *Coumadin/Aspirin Reinfarction Trial (CARS Trial), A Randomized, Double-Blind Study to Compare the Efficacy and Safety of Fixed Low Doses of Coumadin Plus Aspirin to Aspirin Alone in the Prevention of Reinfarction, Cardiovascular Death, and Stroke in Post-Myocardial Infarction Patients*. DUCCS consortium, Dupont Merck Laboratories, 4/1995 - 2/1996 (12 patients enrolled)

Investigator, *Vesnarinone Trial (VEST Trial), A Randomized, Double-Blind, Placebo Controlled, Multiple Dose Study of the Chronic Administration of Vesnarinone in Heart Failure*. Otsuka America Pharmaceutical, Inc., 5/1995 - 8/1996 (13 patients enrolled)
Investigator, *Prospective Randomized Amlodipine Survival Evaluation-2 (PRAISE-2 Study), A Randomized, Double-Blind, Dose-Titration, Parallel Group, Placebo-Controlled Study to Evaluate the Effect of Amlodipine on Survival in Patients with Congestive Heart Failure*. DUCCS Consortium, Pfizer Inc., 1/1996 - 2000 (3 patients enrolled)

Investigator, *Acute Myocardial Infarction Study of Adenosine (AMISTAD study), A Randomized, Open-Label Trial of Adenosine as an Adjunct to rt-PA or Streptokinase (SK) in the Treatment of Acute Myocardial Infarction*. Medco Research, Northwest Medical Center, Margate, FL, 3/1996 - 3/1997 (10 patients enrolled)

Investigator, *Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III study), A Randomized Trial of Reteplase (r-PA) versus Accelerated Alteplase (t-PA) for the Treatment of Acute Myocardial Infarction*. Boehringer Mannheim Therapeutics, University Hospital, Tamarac, FL, 6/1996 - 1/1997 (17 patients enrolled)

Investigator, *Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT study), A Randomized, Double-Blind Evaluation of the Efficacy and Safety of Integrilin*

versus Placebo for Reducing Mortality and (Re)infarction in Patients With Unstable Angina or Non-Q Wave Myocardial Infarction. Merck & Co., Inc., University Hospital, Tamarac, FL, 9/1996 - 1/1997 (8 patients enrolled)

Investigator, *Mode Selection Trial in Sinus Node Dysfunction (MOST study*). National Institutes of Health, University Hospital, Tamarac, FL, Florida Medical Center, Lauderdale Lakes, FL, Northwest Medical Center, Margate, FL, and Coral Springs Medical Center, Coral Springs, FL, 10/1996 - 2001 (19 patients enrolled)

Investigator, *A Randomized, Multicenter, Double-Blind, Placebo-Controlled Forced Dose Titration Study Comparing PPR Verapamil 240 mg/480 mg to Norvasc 5 mg/10 mg With and Without Atenolol 50 mg in Patients With Chronic Stable Angina (Angina study)*. GD Searle and Co., 11/1996 - 4/1997 (2 patients enrolled)
1/29/2025
Investigator, *Clinical Protocol for Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE study)*, GD Searle and Co., 11/1996 - 2001 (25 patients enrolled)

Investigator, *Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE study)*, Astra Hassle AB, 1/1997 - 5/1997 (3 patients enrolled)

Investigator, *Multi-Center, Double-Blind, Randomized, Trial of Single Bolus Lanoteplase Versus Accelerated Alteplase for the Treatment of Subjects With Acute Myocardial Infarction (InTime-II trial)*. Bristol-Myers Squibb, University Hospital, Tamarac, FL, 8/1997 - 1998 (10 patients enrolled)

Investigator, *Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME of CHF trial)*. Sanofi Pharmaceuticals, Inc., University Hospital, Tamarac, FL, Florida Medical Center, Lauderdale Lakes, FL, Northwest Medical Center, Margate, FL, and Coral Springs Medical Center, Coral Springs, FL, 8/1997 - 9/1999 (9 patients enrolled)
Investigator, *Efficacy and Safety of Xemilofiban Administration to Patients Undergoing Coronary Angioplasty or Stent Placement (EXCITE study)*. GD Searle and Co., Florida Medical Center, Lauderdale Lakes, FL, 9/1997 - 1998 (11 patients enrolled)

Investigator, *A Randomized, Double-Blind, Placebo Controlled Trial of the Effect of Weekly Azithromycin on the Incidence of Coronary Artery Disease in Subjects with Evidence of Exposur1/29/2025e to C. Pneumoniae (WIZARD trial)*. Pfizer Central Research, 10/1997 - 2002 (55 patients enrolled)

Investigator, *A Phase III, Randomized, Double-Blind, Parallel-Group, International Trial of Single Bolus TNK-Tissue Plasminogen Activator (t-PA) Versus Accelerated Infusion of rt-PA (Alteplase, Activase) in Acute Myocardial Infarction (ASSENT II trial)*. Boehringer Ingelheim France, Northwest Medical Center, Margate, FL, 12/1997 - 8/1998 (2 patients enrolled)

Investigator, *A Phase III, Multicenter, International, Randomized, Double-Blind, Aspirin-Controlled Study to Evaluate the Efficacy and Safety of Sibrafiban (Ro 48-3657), an Oral Platelet Glycoprotein IIb/IIIa Antagonist, as therapy for the Prevention of Secondary Vascular Events in*

Patients After an Acute Coronary Syndrome (SYMPHONY trial). F. Hoffman-La Roche Ltd., University Hospital, Tamarac, FL, Florida Medical Center, Lauderdale Lakes, FL, Northwest Medical Center, Margate, FL, and Coral Springs Medical Center, Coral Springs, FL, 12/1997-8/1999 (11 patients enrolled)

Investigator, *The Effects of LDL-Cholesterol Lowering Beyond Currently Recommended Minimum Targets on Coronary Heart Disease (CHD) Recurrence in Patients with Pre-Existing CHD (Treating to New Targets, TNT Trial)*. Pfizer/Parke-Davis, 6/1998 - 12/2004 (50 patients enrolled)

Investigator, *COPERNICUS Trial, a Multicenter, Randomized Double-Blind, Placebo-Controlled Study to Determine the Effect of Carvedilol on Mortality in Patients with Severe Chronic Heart Failure (MF 4477/SB 287)*. SmithKline Beecham Pharmaceuticals, 7/1998 - 2000 (6 patients enrolled)

Investigator, *2nd SYMPHONY Trial, a Phase III, Multicenter, International, Randomized, Double-Blind, Aspirin Controlled Trial to Evaluate the Efficacy and Safety of Two Regimens with Xubix™ (Sibrafiban; Ro48-3657), an Oral Platelet Glycoprotein IIb/IIIa Receptor Antagonist, as Therapy for the Long Term Prevention of Secondary Vascular Events in Patients After an Acute Coronary Syndrome*. F. Hoffman-La Roche Ltd., University Hospital, Tamarac, FL, Florida Medical Center, Lauderdale Lakes, FL, Northwest Medical Center, Margate, FL, and Coral Springs Medical Center, Coral Springs, FL, 1/1999 - 8/1999 (4 patients enrolled)

Investigator, *VALIANT Trial, Multinational, Multicenter, Double-Blind, Randomized, Active Controlled, Parallel Group Study Comparing the Efficacy and Safety of Long-Term Treatment with Valsartan, Captopril and their Combination in High-Risk Patients after Myocardial Infarction*. F. Hoffman-La Roche Ltd., University Hospital, Tamarac, FL, Florida Medical Center, Lauderdale Lakes, FL, Northwest Medical Center, Margate, FL, and Coral Springs Medical Center, Coral Springs, FL, 6/1999 - 12/2002 (5 patients enrolled)

Investigator, *ADVANCE Trial, A 12 Week, Double-Blind, Placebo-Controlled Multicenter Study of Oral YM087 (CI- 1025) to Assess Functional Capacity in Patients with Class III Chronic Heart Failure*. Parke-Davis, (Protocol # 1025-14), 1/1999 - 2000 (7 patients enrolled)

Investigator, *CHARM Trial, Candesartan Cilexetil in Heart Failure: Assessment of Reduction in Mortality and Morbidity. Study of Candesartan in Patients with Heart Failure Who are Treated with ACE Inhibitors and Have Depressed Left Ventricular Systolic Function (SH-AHS-006)*. Astra Zeneca, 8/1999 - 7/2003 (14 patients enrolled)

Investigator, GUSTO IV AMI Trial, A Phase II, Randomized, Open-Label Trial Evaluating the Efficacy and Safety of ReoPro® (Abciximab) in Combination with Reduced Dose Retavase®/ Rapilysin™ (Recombinant Plasminogen Activator, Reteplase, r-PA) for the Treatment of Acute Myocardial Infarction (C0116T31). Centocor, University Hospital, Tamarac, FL and Florida Medical Center, Lauderdale Lakes, FL, 9/1999 - 2001 (10 patients enrolled)

Investigator, *WATCH Trial, Warfarin and Antiplatelet Therapy in Chronic Heart Failure,* VA Cooperative Studies Program #442, 10/1999 - 7/2003 (6 patients enrolled)

Investigator, *A 12-Week Multicenter Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ZD4522 in the Treatment of Subjects with Hypertryglyceridemia (4522IL/0035)*. Astra Zeneca, 4/2000 - 2001 (1 patient enrolled)

Investigator, *A 24-Week Randomized Double-Blind Multicenter Trial to Evaluate the Efficacy and Safety of Starting and Maximum Doses of ZD4522 and Atorvastatin in the Treatment of High Risk Hypercholesterolemic Subjects (4522IL/0025)*. Astra Zeneca, 3/2000 - 2002 (3 patients enrolled)

Investigator, *An Open-Label, Multinational, Multicentre, Extension Trial to Investigate the Long-Term Safety and Efficacy of ZD4522 in Subjects in the ZD4522 Clinical Trial Program (ZD4522IL/0034)*. Astra Zeneca, 7/2000 - 11/2004 (3 patients enrolled)

Investigator, *A Randomized, Double-Blind, Comparator-Controlled Study of Pioglitazone HCl vs. Glyburide in the Treatment of Subjects with Type 2 (Non - Insulin Dependent) Diabetes Mellitus and Mild to Moderate Congestive Heart Failure (01-00-TL-OPI-504)*. Takeda Pharmaceuticals, 6/2000 - 1/2004 (3 patients enrolled)

Investigator, *A Randomized, Double-Blind, Comparator-Controlled Study of Pioglitazone HCl vs. Glyburide in the Treatment of Subjects with Type 2 (Non - Insulin Dependent) Diabetes Mellitus and Mild Cardiac Disease (01-00-TL-OPI-520)*. Takeda Pharmaceuticals, 5/2001 - 1/2003 (5 patients enrolled)

Investigator, *Efficacy and Safety Study of the Oral Direct Thrombin Inhibitor H376/95 Compared with Dose-Adjusted Warfarin (Coumadin) in the Prevention of Stroke and Systemic Embolic Events in Patients with Atrial Fibrillation (SPORTIF V) (233:SH-TPA-0005)*. Astra Zeneca, 9/2000 - 3/2003 (6 patients enrolled)

Sub-Investigator, *Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT) (CV 123-229) Protocol (IND Nos. 27,201 and 52,081)*. Bristol Meyers Squibb, 10/2000 - 10/2003 (5 patients enrolled)

Investigator, *A Research Study to Evaluate the Initiation of Coreg at Discharge in Hospitalized Patients with Heart Failure (Initiation Management Predischarge: Assessment of Coreg Therapy for Heart Failure (IMPACT-HF)*. SmithKline Beecham, 9/01 - 2003 (3 patients enrolled)

Investigator, *Irbesartan in Heart Failure with Preserved Systolic Function (I-PRESERVE) (CV 131-148)*. Bristol-Myers Squibb, 8/2002 - 8/2004 (1 patient enrolled)

Investigator, *A Randomized, Double-Blind, Multicenter Study Comparing the Glycemic Control Characteristics of Carvedilol and Metoprolol in Hypertensive Patients with Type II Diabetes Mellitus (GEMINI II), Protocol 105517/346*. GlaxoSmithKline, 4/2002 - 10/2003 (7 patients enrolled)

Investigator, *Aggressive Reduction of Inflammation Stops Events (ARISE), Protocol AGI-1067-042*. AtheroGenics, 8/2003 - 9/2006 (15 patients enrolled)

Investigator, *The Efficacy and Safety of Avalide 150/12.5 mg and Avalide 300/25 mg in Patients with Hypertension Uncontrolled on Monotherapy (INCLUSIVE), Protocol L8829 CV 131-170*. Bristol-Myers Squibb and Sanofi-Synthelabo, 8/2003 - 5/2004 (1 patient enrolled)

Investigator, Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE), Protocol EFC4912. Sanofi-Synthelabo, 9/2003 - 11/2009 (17 patients enrolled)

Investigator, *Trial to Assess Chelation Therapy (TACT), Protocol U01 AT001156-01*. National Heart, Lung and Blood Institute (NHLBI), National Center for Complementary and Alternative Medicine (NCCAM), 10/2003 - 4/2010 (4 patients enrolled)

Investigator, *A 26-week, Double Blind, Randomized, Multi-centre, Phase IIIb, Parallel Group Study to Compare the Efficacy and Safety of Rosuvastatin (40mg) with Atorvastatin (80mg) in Subjects with Hypercholesterolemia and Coronary Heart Disease or CHD Risk Equivalents (POLARIS), Protocol 4522IL/016*. AstraZeneca, 11/2003 - 9/2004 (1 patient enrolled)

Investigator, *A Phase III, Randomized, Double-Blind Study of Intravenous CVT-3146 vs. Adenoscan in Patients Undergoing Stress Myocardial Perfusion Imaging, Protocol CVT 5132*. CV Therapeutics, 6/2004 - 4/2005 (11 patients enrolled)

Investigator, *A Phase III, Randomized, Double-Blind Study of Intravenous CVT-3146 vs. Adenoscan in Patients Undergoing Stress Myocardial Perfusion Imaging, Protocol CVT 5131*. CV Therapeutics, 5/2005 - 10/2006 (16 patients enrolled)

Investigator, *Analysis of a New AT/AF Detection Algorithm in Patients with Atrial Arrhythmias (AWARE)*. St. Jude Medical, 4/2005 - 5/2006 (12 patients enrolled)

Investigator, *A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of Rosuvastatin (Crestor®) 20 mg in the Primary Prevention of Cardiovascular Events Among Subjects with Low Levels of LDL-Cholesterol and Elevated Levels of C-Reactive Protein (JUPITER), Protocol 4522US/0011*. AstraZeneca Pharmaceuticals LP, 7/2005 - 5/2008 (5 patients enrolled)

Investigator, *A Phase III, Multicenter, Randomized, Double-Blind, Placebo-controlled study to Evaluate the Long Term Efficacy and Safety of Oral Tolvaptan in Subjects Hospitalized with Worsening Congestive Heart Failure (EVEREST), Protocol 156-03-236*. Otsuka Maryland Research Institute, Inc., 8/2005 - 10/2006 (4 patients enrolled)

Investigator, *A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention (TIMI 38) (Protocol LY640315)*. Eli Lilly and Company, 10/2005 - 10/2007 (6 patients enrolled)

Investigator, *A Phase III, Parallel, Double-Blind, Multicenter Trial to Examine Inducible Myocardial Perfusion Abnormality Detection With BMS068645 and Adenosine Stress Photon*

Emission Computed Tomography (SPECT) Compared to Coronary Angiography (Protocol BMS068645-302). Bristol-Myers Squibb Medical Imaging, 1/2006 - 2/2006

Investigator, *A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin vs. Simvastatin Monotherapy in High-Risk Subjects Presenting with Acute Coronary Syndrome (IMPROVE-IT), Protocol P04103*. Schering-Plough Research Institute, Inc., 1/2006 - 11/2014 (8 patients enrolled)

Investigator, *Randomized Evaluation of Long term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran etexilate with Open Label warfarin for the Prevention of Stroke and Systemic Embolism in Patients with Non-valvular Atrial Fibrillation: Prospective, Multi-centre, Parallel-group, Non-inferiority trial*. Boehringer Ingelheim International GmbH, 2/2006 - 2/2009 (19 patients enrolled)

Investigator, *Follow-up of Clinical Outcomes: The Long Term AGI-1067 plus Usual Care Study (FOCUS), Protocol AGI-1067-051*. AtheroGenics Inc., 9/2006 - 6/2007 (11 patients enrolled)

Investigator, *Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE-HF)*. Protocol AMG-04-002, Medtronic Inc., 5/2005 - 10/2009 (95 patients registered)

Investigator, *A Placebo-controlled, Double-blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400mg bid for the Prevention of Cardiovascular Hospitalization or Death from any Cause in Patients with Atrial Fibrillation/Atrial Flutter (ATHENA).* Protocol EFC5555, Sanofi~Sythelabo/Aventis, 7/2005 - 3/2008 (1 patient enrolled)

Investigator, *A Prospective, Randomized, Double-blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) with Adjusted-Dose Oral Warfarin for the Prevention of stroke and Non-Central Nervous System Systemic Embolism in Subjects with Non-valvular Atrial Fibrillation (ROCKET AF, Protocol 39039039AFL3001*. Johnson and Johnson Pharmaceutical Research and Development, LLC, 2/2007 - 10/2010 (9 patients enrolled)

Investigator, *A Randomized, Double-blind Trial to Test Higher versus Lower Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation and Endothelial Function in Secondary Prevention (TAD)*. Bayer, 10/2006 - 6/2007 (30 patients enrolled)

Investigator, *A Multicenter, Randomized, Double-blind, Prospective Study Comparing the Safety and Efficacy of Fenofibric Acid and Simvastatin Combination Therapy to Fenofibric Acid and Simvastatin Montherapy in Subjects with Mixed Dyslipidemia, Protocol M05-749*. Abbott, 5/2006 - 6/2007 (1 patient enrolled)

Investigator, *Registry of AT/AF Episodes in the CRM Device Population: RATE Registry*. St. Jude Medical, 6/2007 - 4/2011 (7 patients enrolled)

Investigator, *The TIMI-38 Coronary Stent Registry: Long-Term Follow Up of Subjects with PCI and Stenting for ACS*. Eli Lilly and Company, 4/2007 - 10/2010 (6 patients enrolled)

Investigator, *A Study of Telemonitoring to Improve Heart Failure Outcomes (Tele-HF).* National Institute of Health, 9/2007 - 9/2010 (21 patients enrolled)

Investigator, *Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or are Unsuitable for Vitamin K Antagonist Treatment: A Randomized Double Blind Trial (AVERROES)*. Bristol-Myers Squibb, 12/2007 - 8/2010 (4 patients enrolled)

Investigator, *Warfarin Versus Aspirin In Reduced Cardiac Ejection Fraction (WARCEF)*. National Institute of Neurological Disorders and Stroke, 5/2007 - 8/2013 (3 patients enrolled)

Investigator, *Protocol CDx000004: Identification of Gene Expression Patterns in Circulating Cells that Predict the presence of Coronary Artery Disease - The PREDICT Study - Personalized Risk Evaluation and Diagnosis In the Coronary Tree*. Cardio Dx Inc, 10/2008 - 2/2011 (13 patients enrolled)

Investigator, *Protocol 3606-CL-3002 A Phase 3b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Caffeine Intake on Single Photon Emission Computed Tomography (SPECT). Myocardial Perfusion in Subjects Administered Regadenoson*. Astellas, 12/2008 - 9/2010 (2 patients enrolled)

Investigator, *Protocol DU176b-C-U301 - A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Multicenter, Multi-national Study For Evaluation of Efficacy and Safety Of DU-176b Versus Warfarin in Subjects with Atrial Fibrillation - Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation (ENGAGE-AF)*. Daiichi Sankyo, 1/2009 - 8/2013 (8 patients enrolled)

Investigator, *Protocol 1160.71: Long Term Multi-Center Extension of Dabigatran Treatment in Patients with Atrial Fibrillation Who Completed the RE-LY trial and a Cluster Randomised trial to Assess the Effect of a Knowledge Translation Intervention on Patient Outcomes (RELY-ABLE).* Boehringer Ingelheim International, 3/2009 - 7/2011 (13 patients enrolled)

Investigator, *Protocol BC22140 ROW: A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Cardiovascular Outcomes Study to Evaluate the Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With a Recent Acute Coronary Syndrome (ACS) Event and Type 2 Diabetes - ALECARDIO*. Hoffman-La Roche, Inc, 2/2010 - 8/2013 (2 patients enrolled)

Investigator, *Protocol D1680C00003: A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients with Type 2 Diabetes - SAVOR-TIMI 53*. AstraZeneca, 4/2010 - 7/2013 (14 patients enrolled)

Investigator, *DUCCS-BI Registry: A Retrospective Study to Assess the Quality of Anticoagulation with Warfarin in Patients with Nonvalvular Atrial Fibrillation*.

Investigator, *Protocol RIVAROXAFL4001: A Multicenter, Prospective Outpatient Disease Registry to Identify "Real World" Treatment Patterns of Atrial Fibrillation According to Patient*

Demographics, Clinical Factors, Risk Stratification and Geographic Regions - ORBIT-AF. Janssen Scientific Affairs, LLC, 5/2010 - 6/2014 (53 patients enrolled)

Investigator, *PROMISE: A Multicenter Randomized Trial to Determine Whether an Initial Non-invasive Anatomic Imaging Strategy with Coronary CT angiography (CTA) Will Improve Clinical Outcomes in Subjects with Symptoms Concerning for Coronary Artery Disease Relative to an Initial Functional Testing Strategy (Usual Care)*. National Heart, Lung and Blood Institute (NHLBI), 5/2010 - 12/2013 (5 patients enrolled)

Investigator, *D5132C00001: A Randomized, Double-blind, Placebo controlled, Parallel group, Multinational trial, to Assess the Prevention of Thrombotic Events with Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients with History of Myocardial Infarction - PEGASUS-TIMI 54*. AstraZeneca, 3/2011 - 4/2015 (6 patients enrolled)

Investigator, *A Randomized, Double-blind, Placebo Controlled Trial to Compare the Efficacy of Bridging Anticoagulation (Therapeutic Dose LMWH) with No Bridging Anticoagulation (Placebo) on the Rate of ATE in Patients with Atrial Fibrillation or Atrial Flutter Who Require Temporary Interruption of Warfarin - The 'BRIDGE' Trial*. National Institutes of Health, National Heart, Lung, and Blood Institute, 1/2012 - 9/2013 (2 patients enrolled)

Investigator, *Protocol 1160.128: A Prospective, Open Label Study Evaluating the Efficacy of Two Management Strategies (Pantoprazole 40 mg q.a.m. and Taking Pradaxa® with Food (Within 30 minutes After a Meal)) on Gastrointestinal Symptoms (GIS) in Patients Newly on Treatment with Pradaxa® 150 mg b.i.d. or 75 mg b.i.d. for the Prevention of Stroke and Systemic Embolism in Patients with Non-valvular Atrial Fibrillation (NVAF)*. Boehringer Ingelheim, 8/2012 - 9/2014 (3 patients enrolled)

Investigator, *Protocol TAK-875-306: A Multicenter, Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Evaluate Cardiovascular Outcomes of TAK-875, 50 mg in Addition to Standard of Care in Subjects with Type 2 Diabetes and with Cardiovascular Disease or Multiple Risk Factors for Cardiovascular Events - Grand 306*. Takeda Development Center America, Inc., 10/2012 - 6/2014 (7 patients enrolled)

Investigator, *GUIDing Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure - GUIDE-IT*. National Institutes of Health, National Heart, Lung, and Blood Institute, 1/2013 - 01/2017 (6 patients enrolled)

Investigator, *Protocol RIVAROXAFL4002: A Multicenter, Prospective Outpatient Disease Registry to Evaluate the Utilization of Target-Specific Antithrombotic Agents, Such as FXa (factor Xa) Inhibitors and Direct Thrombin Inhibitors, and Associated Outcomes - ORBIT-AF II*. Janssen Scientific Affairs, LLC, 3/2013 - 07/2017 (100 patients enrolled)

Investigator, *Protocol D1693C00001: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes - DECLARE-TIMI 58*. AstraZeneca, 5/2013 - 3/2018 (15 patients enrolled)

Investigator, *Protocol CACZ885M2301: A Randomized, Double-blind, Placebo-Controlled, Event Driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-Myocardial Infarction Patients with Elevated hsCRP - CANTOS*. Novartis Pharmaceuticals Corporation 5/2013 - 12/2017 (2 patients enrolled)

Investigator, *Protocol BAY 59-7939/157 86: A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients with Coronary or Peripheral Artery Disease - COMPASS - Cardiovascular Outcomes for People using Anticoagulation Strategies*. Bayer/PHRI, 11/2013 - 3/2018 (16 patients enrolled)

Investigator, *Protocol APD356-G000-401: A Randomized, Double-blind, Placebo-Controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment with BELVIQ (locaserin HC1) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects with Cardiovascular Disease or Multiple Cardiovascular Risk Factors - CAMELLIA TIMI-61*. Eisai, 4/2014 - 3/2018 (15 patients enrolled)

Investigator, *Protocol D513BC00001: A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor 90 mg twice daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients with Type 2 Diabetes Mellitus - THEMIS.* AstraZeneca, 5/2014 - 3/2018 (4 patients enrolled)

Investigator, *Protocol GLP116174: A Long Term, Randomized, Double Blind, Placebo-controlled Study to Determine the Effect of Albiglutide, when added to standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Patients with Type 2 Diabetes Mellitus - HARMONY OUTCOMES.* GlaxoSmithKline, 9/2015 - 3/2018 (4 patients enrolled)